Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

Authors:

Abstract
No abstract available
Funding Information
  • Sanofi
  • Biomedical Advanced Research and Development Authority

This publication has 20 references indexed in Scilit: